Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Evelyn Jackson

Internal Medicine Clarksville, MD Medical Doctor

NPI 1770707093 CMS profile 79918

5540 Ten Oaks Road, Suite 200, Clarksville, MD 21029

Open in the dashboard

General payments

$2,610

153 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Evelyn Jackson of Clarksville, MD is reported in the CMS Open Payments database as having received $2,610 across 153 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $259 12
2024 General $301 14
2023 General $315 17
2022 General $546 37
2021 General $527 35
2020 General $319 19
2019 General $343 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Evelyn Jackson
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Evelyn Jackson were reported at $259. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Evelyn Jackson Internal Medicine median Middle half National median
2019 $343 $159 $48–$570 $163
2020 $319 $119 $33–$402 $114
2021 $527 $135 $37–$521 $132
2022 $546 $141 $42–$496 $149
2023 $315 $149 $45–$519 $160
2024 $301 $154 $47–$537 $164
2025 $259 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $466 33 payments
  2. Novo Nordisk Inc $396 27 payments
  3. E.R. Squibb & Sons, L.L.C. $352 20 payments
  4. Amgen Inc. $255 13 payments
  5. Pfizer Inc. $204 11 payments
  6. Lilly USA, LLC $196 11 payments
  7. Merck Sharp & Dohme Corporation $186 9 payments
  8. Exact Sciences Corporation $72 4 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $64 2 payments
  10. GlaxoSmithKline, LLC. $57 3 payments
  11. Other $361 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,595 152 payments
  2. Education $15 1 payment
Products named General payments · program years 2019–2025
  1. ELIQUIS Cardiovascular $326 19 payments
  2. Ozempic $269 18 payments
  3. RYBELSUS $232 16 payments
  4. ELIQUIS Cardiovascular;Metabolic Disease $204 11 payments
  5. QULIPTA $197 14 payments
  6. EVENITY $175 9 payments
  7. NURTEC ODT $165 8 payments
  8. Prolia $157 8 payments
  9. GARDASIL 9 $136 6 payments
  10. SYNTHROID $125 9 payments
  11. Other $1,838 102 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 151 drugs

Part D claims

8,087

Median for Internal Medicine: 777

Drug cost

$575,988

Median for Internal Medicine: $73,373

Branded share of claims

21%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 166 $143,333
Ozempic Semaglutide Brand 85 $98,364
Januvia Sitagliptin Phosphate Brand 32 $37,235
Trulicity Dulaglutide Brand 24 $31,154
Farxiga Dapagliflozin Propanediol Brand 24 $19,347
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 22 $15,888
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 38 $13,446
Brilinta Ticagrelor Brand 11 $12,091
Rybelsus Semaglutide Brand 12 $11,921
Breo Ellipta Fluticasone/Vilanterol Brand 15 $9,034

The 10 drugs with the highest cost, of 151 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$176,504

Of which drugs: $5,425

Medicare patients

668

Average age 77

Services billed

3,108

449 women, 219 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 37%
Diabetes 22%
Ischemic heart disease 16%
Atrial fibrillation 15%
Depression 12%
Osteoporosis 12%
Cancer 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 70 72 $4,969

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • PFIZER INC. $27
  • E.R. Squibb & Sons, L.L.C. $20
$47 166 —
NURTEC ODT
  • PFIZER INC. $27
$27 — —
UBRELVY
  • AbbVie, Inc. $26
$26 — —
QULIPTA
  • AbbVie, Inc. $26
$26 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $26
$26 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

153 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record